With all the drug repurposing work and truckloads of other tasks from our customers sitting on our (mostly virtual) desks, H. M. Pharma Consultancy hasn't reported on its patent database project for a long time now. Its not that we had pushed it into the backseat: we all are multitaskers, constantly running THIRDSPACE data collection and data cleaning work as tightly coordinated background process...

We are expanding our presence on Google Plus with a company page. This is where all of the brief ad-hoc posts or notices that concern our enterprise or its immediate business environment will be consolidated for your convenience. The more extensive and/or more formal discussions will continue to be posted on this blog.If you are on Google+ please include the H.M. Pharma Consultancy e.U. page in yo...

Here are five new drug repurposing patent applications picked and commented for you, (almost) fresh online on PatentScope! - Please attribute to H.M. Pharma Consultancy when citing from this post.And we are happy to announce two very positive events:(1) On October 23rd,'s CEO Hermann Mucke will be a virtual presenter at Arrowhead's 2nd Annual Repositioning & Indications Discovery Conference in...

Two weeks ago we concluded the World Drug Repositioning Congress Europe, a fabulous three-day meeting in London organized by Terrapinn and the first of three major drug repurposing conferences due in 2012. Its transatlantic counterpart - the World Drug Repositioning Congress USA - will take place on December 4-5 in Washington DC. Inbetween, Arrowhead will hold its 2nd Annual Repositioning & In...

Finding new uses for known drugs and drug candidates is gaining momentum, and has been on the rise for the past 12-18 months -- this is clearly to be seen in the output of international Patent Convention Treaty documents that are published every week. There is no patent code or other easy modality to identify patent applications that concern drug repurposing, you must look at every single document...

The repurposing community has been inordinately busy and creative during the months when the PCT disclosures that are now being rolled out were filed. In fact there are so many documents in our hold file right now that we are only doing about half the evaluations now -- more is to follow in one or two batches later in August. Here's what we are presenting today: cannabinoid receptor ligands for en...

This is a brief summary of the past 8 months' discussion highlights in our discussion group, "Drug Repurposing-Reprofiling-Repositioning." If you want to learn about the details, join our 383 members!-----December 2011 -- Group members Lun Yang and Pankaj Agarwal have a paper in PLoS One: "Systematic Drug Repositioning Based on Clinical Side-Effects"January 2012 -- The group discusses a blog post ...

Its a weekend again -- a time to relax a bit from the deadline-driven consulting work (interesting as it is), and a time to share data and opinions on a few drug repurposing patents which crossed our desks during the past weeks. We have: an oxycodone/naloxone combination for multiple symptoms of Parkinson's disease; an abandoned antihyperlipidemic for pancreatitis; a nootropic for benign tremor; a...

"EU agency lifts lid on drug data secrets," the newswires blared on the otherwise calm summer Sunday afternoon of July 15, 2012.The usual full-time critics of the pharmaceutical industry, in alliance with the pirates and privateers who abhor the idea of anything digital not being available at a mouseclick, have long demanded it. Now the European Medicines Agency (EMA) did not only cave in to these...

Doing business is not always easy for H.M. Pharma Consultancy, and in some respects this is especially true for our home turf, Austria. It's a small country, and one not globally notable for its pharma or biotech industry. So its quite a rare event if a domestic potential new customer approaches us with an inquiry that is substantial enough to require a bit of due diligence from their side. Inevit...